Investigates CD36's role in regulating CD11c+ T-bet+ B cell activation, suggesting metabolic insights for inflammation management.
Introduction B cells expressing the pro-inflammatory transcription factor T-bet have been implicated in a variety of disease states, including obesity, aging, and autoimmunity. The dependence of this subset on innate signaling via TLR7/9 agonism in the presence of IFNg and IL-21 has been well characterized. However, less is known about the metabolic requirements that may sustain this population during chronic inflammation. Our laboratory has observed that CD11c+ T-bet+ B cells from murine tissues express high levels of the scavenger receptor/fatty acid translocase CD36, suggesting a critical role for this receptor in T-bet+ B cell differentiation and/or function. Methods To investigate the role of CD36 in this subset, a B cell-specific CD36 knockout was generated using Cre-Lox recombination. Splenic B cells from control or knockout mice were stimulated in vitro with the TLR7 agonist R848, oxLDL, or both. Flow cytometry was used to assess B cell expression of T-bet, CD36, CD86, and MHC-II. Reactive oxygen species (ROS) were also measured using CellROX Green. In vivo, expansion of splenic CD11c+ T-bet+ B cells was evaluated following R848 administration or high-fat diet (HFD) feeding. Results We found that in vitro, R848 drives T-bet and CD36 expression in B cells, resulting in intracellular accumulation of neutral lipids. B cells lacking CD36 had reduced levels of CD86, but not MHC-II, after stimulation with oxLDL, R848, or their combination. Cellular ROS levels, however, were not impacted by CD36 deletion in any stimulation condition. In vivo, deletion of CD36 from B cells was also found to significantly and selectively limit the expansion of splenic CD11c+ T-bet+ B cells following administration of R848, or after HFD. Conclusion Taken together, these findings implicate CD36 as a metabolic regulator of T-bet+ B cell differentiation and activation. Further work will delineate how CD36 integrates lipid uptake with immune signaling to shape T-bet+ B cell responses during chronic inflammation. Funding Source National Institutes of Health grant K12 GM111726.
No takes yet. Share an insight, caveat, or question.
Enslow et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: